On August 30, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 1:30 p.m. EST (Press release, Bio-Techne, AUG 30, 2022, View Source [SID1234618755]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2022 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City (Press release, Aptose Biosciences, AUG 30, 2022, View Source [SID1234618754]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. William G. Rice, Chairman, President and CEO of Aptose, will deliver the Company presentation on Tuesday, September 13, 2022, at 11:30 a.m. ET, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.

H.C. Wainwright 24th Annual Global Investment Conference

On August 30, 2022 The Roche Investor Relations team would like to invite you to the Roche Pharma Day that will take place in London on Monday, 12th September 2022, starting at 10:30 BST and will finish at 14:30 BST with a reception (Press release, Hoffmann-La Roche, AUG 30, 2022, View Source [SID1234618751]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Roche Pharma Day will address the following topics:

Pharma strategy, portfolio planning, productivity & new technologies
Market opportunities, on-going launches, pricing & access
Late stage pipeline update in oncology, neuroscience, immunology, infectious diseases & ophthalmology

Speakers will include Bill Anderson, Teresa Graham, Levi Garraway, Paulo Fontoura and Christopher Brittain. You will have the opportunity to meet senior management during the event.

On August 30, 2022 Patrys’ appointed Contract Development Manufacturing Organisation (CDMO) reported that has successfully completed specification testing of PAT-DX1 drug substance produced in the recently-completed engineering run, laying strong foundations for the Company’s planned phase 1 clinical trial next year (Press release, Patrys, AUG 30, 2022, View Source [SID1234618730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Specification, or batch release, testing is a necessary requirement to ensure high quality pharmaceuticals are used in GMP and clinical studies.

On August 29, 2022 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) reported that the newly developed humanized IgG1 CD70 antibody (project number: IMM40H) has been approved by the US FDA and China NMPA for Clinical trial research almost simultaneously (Press release, ImmuneOnco Biopharma, AUG 29, 2022, View Source [SID1234655666]). This is the third IND approval from the FDA so far (previously, IMM0306 and IMM2902) and it is another important milestone in clinical development of the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CD70 highly and widely expresses in many tumor tissue. Its ligand CD27 expresses on regulatory T (Treg) cells. CD70/CD27 interaction activates Treg cells which depress Tumor immunity. In vivo efficacy studies show that IMM40H has strong antitumor activities. Subcutaneously implanted tumors can be eliminated completely after 2-3 treatments at low doses.

Chairman, Founder of ImuneOnco, Dr.Tian Wenzhi said: "I am very pleased that the IMM40H we newly developed is approved by the US FDA and China NMPA for clinical trial research. We feel confident about clinical developmental value of IMM40H. We will actively promote clinical trial research and strive to bring it to the market as soon as possible, so as to benefit the cancer patients as soon as possible. "